Press Releases + New

Date Title and Summary View
Toggle Summary Galectin Therapeutics Planning Clinical Trials for Early 2013 to Treat Fatty Liver Disease with Advanced Fibrosis After Recent FDA Meeting View HTML
Toggle Summary Galectin Therapeutics Receives U.S. Patent for Potential Ground-Breaking Treatment for Chronic Liver Disease with Fibrosis (Scarring) and Cirrhosis View HTML
Toggle Summary Galectin Therapeutics Announces Addition to Russell Microcap Index View HTML
Toggle Summary Galectin Therapeutics to Host Symposium on Galectin Science and Therapeutic Applications September 17-19, 2012 View HTML
Toggle Summary Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders View HTML
Toggle Summary Galectin Therapeutics Announces Initiation of Phase 1/2 Trial of Novel Combination Therapy for Advanced Metastatic Melanoma View HTML
Toggle Summary Galectin Therapeutics Reports First Quarter 2012 Financial Results View HTML
Toggle Summary Galectin Therapeutics Announces Long-term Engagement of Dr. Scott Friedman to Advise on Liver Fibrosis Programs
-Renowned Physician and Researcher in Liver Diseases-
View HTML
Toggle Summary Galectin Therapeutics to Present Promising New Therapeutic Approach for Fatty Liver Disease at Digestive Disease Week 2012 View HTML
Toggle Summary Galectin Therapeutics Reports Full Year and Fourth Quarter 2011 Financial Results View HTML